| Immunogenicity of biologics in inflammatory bowel disease |
30 |
| The gut virome: the 'missing link' between gut bacteria and host immunity? |
24 |
| Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence |
20 |
| Proton-pump inhibitors among adults: a nationwide drug-utilization study |
19 |
| New biologics and small molecules in inflammatory bowel disease: an update |
19 |
| Insights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease |
17 |
| The controversial role of Enterococcus faecalis in colorectal cancer |
16 |
| Cholestatic liver diseases: new targets, new therapies |
14 |
| Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions |
12 |
| Inflammatory bowel disease: towards a personalized medicine |
11 |
| Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician |
11 |
| Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management |
11 |
| Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis |
10 |
| The main contributor to the upswing of survival in locally advanced colorectal cancer: an analysis of the SEER database |
8 |
| Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions |
8 |
| Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint |
8 |
| Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date |
8 |
| The intestinal vitamin D receptor in inflammatory bowel disease: inverse correlation with inflammation but no relationship with circulating vitamin D status |
8 |
| Management of Clostridioides difficile colitis: insights for the gastroenterologist |
8 |
| Targeting liver cancer stem cells for the treatment of hepatocellular carcinoma |
8 |
| The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease |
8 |
| Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience |
7 |
| Long noncoding RNA AOC4P regulates tumor cell proliferation and invasion by epithelial-mesenchymal transition in gastric cancer |
7 |
| Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017 |
7 |
| The role of the gastric bacterial microbiome in gastric cancer: Helicobacter pylori and beyond |
7 |
| Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease? |
7 |
| Chinese herbal medicine for functional dyspepsia: systematic review of systematic reviews |
7 |
| Cost savings following faecal microbiota transplantation for recurrent Clostridium difficile infection |
7 |
| The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma |
6 |
| The Lewis score or the capsule endoscopy Crohn's disease activity index: which one is better for the assessment of small bowel inflammation in established Crohn's disease? |
6 |
| Characterization of the prognostic values of the NDRG family in gastric cancer |
6 |
| Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment? |
6 |
| Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective |
6 |
| Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities |
6 |
| Impact of an optimized colonoscopic screening program for patients with Lynch syndrome: 6-year results of a specialized French network |
6 |
| Susceptibility-guided therapy for Helicobacter pylori infection treatment failures |
6 |
| Targeting mucosal healing in Crohn's disease: what the clinician needs to know |
6 |
| Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials |
6 |
| Emerging concepts in non-invasive monitoring of Crohn's disease |
6 |
| Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients |
6 |
| Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention |
6 |
| Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn's disease: systematic review and meta-analysis |
5 |
| Progress and challenges in the management of diverticular disease: which treatment? |
5 |
| Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation |
5 |
| Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels |
5 |
| Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity |
5 |
| Advances in therapeutic options for portal hypertension |
5 |
| Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence |
5 |
| Insights into the role of cannabis in the management of inflammatory bowel disease |
5 |
| Host-targeting therapies for hepatitis C virus infection: current developments and future applications |
5 |
